Section | Outcome Measures | |
---|---|---|
r | P value | |
Intention | ||
Warnings and precautions | −0.39 | <.001 |
Adverse reactions | −0.39 | <.001 |
Drug interactions | −0.36 | <.001 |
Use in specific populations | −0.39 | <.001 |
Overdosage | −0.34 | <.001 |
Description | −0.44 | <.001 |
Clinical studies | −0.33 | .001 |
Perceived benefit | ||
Warnings and precautions | −0.28 | .002* |
Adverse reactions | −0.28 | .002* |
Description | −0.36 | <.001 |
Perceived safety | ||
Warnings and precautions | −0.32 | <.001 |
Adverse reactions | −0.32 | <.001 |
Description | −0.34 | <.001 |
↵* These associations were no longer significant with covariates in the model (r = −0.25; P = .007).